Reports: Merz Pharmaceuticals sues Par over cerebral palsy drug

Par sought approval for generic version of Cuvposa

NEW YORK — Drug maker Merz Pharmaceuticals is suing Par Pharmaceutical over the latter's attempt to market a generic drug for cerebral palsy patients, according to published reports.

Bloomberg reported that Merz sued Par in the U.S. District Court for the District of Delaware after Par attempted to apply for Food and Drug Administration approval for a generic version of Cuvposa (glycopyrrolate) oral solution, used to treat severe drooling in cerebral palsy patients.

The drug received FDA approval this year, and Merz bought rights to the drug in August.

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 


- 11:41 PM
Steveadams says

How he has applied for the Food and Drug Administration..? How much time will it take to be approved..? estimation immobiliere

Login or Register to post a comment.